Epidarex Capital IV
Epidarex Capital
◆ Investment Thesis
Focus on breakthrough academic and translational research for the creation of therapeutics and medical device companies, targeting significant unmet medical needs.
◆ About Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm focused on building early-stage life science and health technology companies addressing major unmet needs in oncology, cardiometabolic, autoimmune, and neurological conditions. The firm leads early-stage financings, including Series A rounds, to bridge the equity funding gap for spinouts from UK and US research hubs, partnering with top scientists and entrepreneurs to build leadership teams and progress through key milestones. Epidarex Capital IV, LP has secured over $145 million in commitments and plans to invest in up to 15 companies.
◆ Sectors
◆ Stages
◆ Geography Focus
◆ Notable Investments
◆ Traits
Leads rounds
Co-invests
◆ FAQ
What does Epidarex Capital IV invest in?
Epidarex Capital IV invests in Biotech, Medtech and Drug Discovery at the seed stage.
Which geographies does Epidarex Capital IV focus on?
Epidarex Capital IV focuses on United Kingdom and United States, and is headquartered in UK.
What is Epidarex Capital IV's typical check size?
Epidarex Capital IV typically writes checks of $1M to $10M.